5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Market is Segmented by Disease Type (Systemic Autoimmune Disease and Localized Autoimmune Disease), Diagnostic Technique, and Geography.
The major factors driving the market are the increasing prevalence, along with the rising public awareness, technological advancements, and improved laboratory automation.
European countries are being confronted with an increase in the occurrence of the most autoimmune immune disorders. The prevalence rate of multiple sclerosis in Europe is estimated at 83 out of 100,000. Moreover, multiple sclerosis is more common among women than men. In addition, two million people are affected by rheumatoid arthritis and nearly 2-3% of the population is estimated to be affected by psoriasis, which is one of the most common forms of autoimmune diseases. Owing to the aforementioned conditions, early diagnosis and onset of treatment can make a significant difference in preventing permanent damage and disability. Results of autoimmune disease diagnostic tests can confirm a disorder, estimate disease severity, aid in assessing prognosis. They are also useful to follow disease activity.
The increasing awareness of auto-immune diseases, through programs of research, education, support, and advocacy is a key factor augmenting the usage rates. The European Commission is taking several steps to increase awareness among the public regarding the risk factors in developing autoimmune diseases. Thus, as symptoms occur, they can seek diagnosis and begin a treatment regimen.
An autoimmune disease is a condition that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune diseases.
|By Disease Type|
|By Diagnostic Technique|
|Immunofluorescence Assays (IFA)|
|Enzyme-linked Immunosorbant Assay (ELISA)|
|Other Diagnostic Techniques|
Report scope can be customized per your requirements. Click here.
Rheumatoid arthritis is a chronic, progressive, and inflammatory autoimmune disease associated with HLA-DR4 and HLA-DR1 serotypes, characterized by persistent inflammation of the synovium that leads to the destruction of joints. The availability of treatment options, such as biologics, increasing awareness about rheumatoid arthritis, and the presence of reimbursement schemes across many countries are driving the growth of the segment. Rheumatoid arthritis (RA) is more prevalent in females. For instance, the United Kingdom has a prevalence rate of 1.2% in females and 0.4% in males.
Increasing incidence of autoimmune diseases, off-label prescription of NSAIDs, and other pain management drugs are expected to increase the demand for RA diagnosis. In addition, extensive focus on the high specificity and sensitivity of RA kits from kit manufacturers, and favorable regulatory guidelines for rapid RA diagnostic kits are expected to fuel the market growth.
To understand key trends, Download Sample Report
The European autoimmune disease diagnostics market is moderately competitive in nature. Some of the well-known players in the market are Abbott Laboratories, Biomérieux, Bio-rad Laboratories, F. Hoffmann-la Roche, and Thermo Fisher Scientific Inc. However, there are some new companies that are focusing on market penetration, owing to the growing market for autoimmune disease diagnostics in Europe.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence and Rising Public Awareness
4.2.2 Technological Advancements and Improved Laboratory Automation
4.3 Market Restraints
4.3.1 Slow Turnaround Time of Results and Need of Multiple Diagnostic Test
4.3.2 High Cost
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Disease Type
5.1.1 Systemic Autoimmune Disease
220.127.116.11 Rheumatoid Arthritis
18.104.22.168 Systemic Lupus Erythematosus (SLE)
22.214.171.124 Multiple Sclerosis
126.96.36.199 Other Systemic Autoimmune Diseases
5.1.2 Localized Autoimmune Disease
188.8.131.52 Inflammatory Bowel Disease
184.108.40.206 Type-1 Diabetes
220.127.116.11 Other Localized Autoimmune Diseases
5.2 By Diagnostic Technique
5.2.1 Immunofluorescence Assays (IFA)
5.2.2 Enzyme-linked Immunosorbant Assay (ELISA)
5.2.3 Western Blotting
5.2.4 Multiplex Immunoassay
5.2.6 Other Diagnostic Techniques
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Biomerieux Inc.
6.1.3 Bio-rad Laboratories
6.1.4 Euroimmun AG
6.1.5 F. Hoffmann-la Roche
6.1.6 Inova Diagnostics Inc.
6.1.7 Myriad Genetics
6.1.8 Siemens Healthineers Inc.
6.1.9 Thermo Fisher Scientific Inc.
6.1.10 Trinity Biotech PLC
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments